Related Experiment Video
Updated: Jan 22, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Research progress in precision medicine for type 2 diabetes based on the GLP-1
Sangui Wang1,2, Chenrong Yuan3, Haifeng Wang1
1Department of Surgery, Dongguan Nancheng Hospital, Dongguan, China.
Type 2 Diabetes Mellitus (T2DM) is a growing global health threat. This review covers new treatments like glucagon-like peptide-1 (GLP-1) therapies and metabolic surgery for T2DM management.
Area of Science:
- Endocrinology and Metabolism
- Gastroenterology
- Surgical Innovation
Background:
- Type 2 Diabetes Mellitus (T2DM) affects 9% of the global population, with rising prevalence and younger onset.
- T2DM is a complex metabolic disorder involving insulin resistance and pancreatic beta-cell dysfunction, linked to obesity and cardiovascular disease.
- Current T2DM management strategies are evolving, with significant advancements in therapeutic targets.
Purpose of the Study:
- To comprehensively review current trends in T2DM treatment.
- To explore the molecular profile and biological characteristics of GLP-1 and L-cells.
- To examine the development of GLP-1-related pharmaceuticals and advances in metabolic surgery for T2DM.
Main Methods:
- Literature search of PubMed, Embase, and SciELO databases up to June 2025.
- Inclusion of basic/mechanistic studies, observational studies, and clinical trials.
- Keywords included "diabetes", "type 2 diabetes mellitus", "glucagon-like peptide-1", "L-cell", "metabolic surgery", and "GLP-1 receptor agonists".
Main Results:
- Glucagon-like peptide-1 (GLP-1) based therapies are now a cornerstone in T2DM management.
- Metabolic surgery shows significant potential in ameliorating T2DM symptoms.
- The review synthesizes data on GLP-1 biology, pharmaceutical development, and surgical interventions.
Conclusions:
- GLP-1 therapies and metabolic surgery represent key advancements in T2DM treatment.
- Understanding L-cell biology and GLP-1 pathways is crucial for developing novel therapeutics.
- Future personalized precision medicine strategies for T2DM can benefit from these insights.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Overview
The nitrous acid is unstable. Hence, it is formed in situ from a solution of sodium nitrite and cold aqueous acids such as hydrochloric or sulfuric acid. In an acidic solution, the –OH group of nitrous acid undergoes protonation to give oxonium ion, followed by...
1° Amines to Diazonium or Aryldiazonium Salts: Diazotization with NaNO2 Mechanism

